The World Health Organization (WHO) on Monday issued its first-ever global guidelines on the use of GLP-1 medications for treating obesity as a chronic illness. In a press release, the WHO said this ...

New World Health Organization guidelines for GLP-1 weight-loss drugs state that “intensive behavioral therapy” should be combined with these revolutionizing medications for obesity treatment. In the ...

The World Health Organization is officially backing popular weight-loss drugs like Ozempic and Wegovy. The WHO published new guidelines about glucagon-like peptide-1 (GLP-1) medications in the medical ...

In a move that could reshape how doctors approach both weight and heart health, the American College of Cardiology (ACC) released new guidance today recommending the use of popular weight-loss ...

Experts say the official recommendation reemphasizes the game-changing ability of GLP-1 medications, but stress that diet and exercise are integral to an effective treatment plan for obesity. The ...

A new World Health Organization (WHO) guideline recommending GLP-1s for obesity treatment along with recent efforts to reduce the drugs’ costs are unlikely to change US obesity practice — but actions ...

The WHO has just released landmark global guidelines recommending for the first time that GLP-1 medicines may be used for long-term treatment of obesity in adults. The move comes as obesity rates ...

Preoperative GLP-1 therapy may reduce surgical risks in obese patients without increasing perioperative complications, offering a scalable weight management strategy. Updated ASA guidelines recommend ...

American Academy of Pediatrics guidelines that set off a new era in obesity treatment — and a national debate about whether children should be prescribed weight loss drugs — may have been shaped by ...

GLP-1 is a hormone that plays a key role in glucose metabolism and appetite regulation Obesity affects more than one billion people worldwide. To address this growing health challenge, the World ...

The World Health Organisation (WHO) has released a guideline on the use of Glucagon-Like Peptide-1 (GLP-1) therapies for treating obesity as a chronic disease. In September 2025, the WHO added GLP-1 ...